News

As per the exclusive marketing agreement, the Herbagenix division of Hemp will distribute the product throughout the US, Canada, and Mexico. Designed to help baby boomers and enhance

Developed by Nitto Denko in partnership with Toa Eiyo, the medicine is marketed by Toa Eiyo, distributed and sold by Astellas Pharma as the world’s first transdermal ß1-blocker

The study compared Eliquis as a single-agent against compared to current standard of care in 5,395 patients with confirmed symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE)

The collaboration will leverage Immunocore’s ImmTAC technology directed towards the cancerous cells avoiding damage to healthy cells and the intracellular changes that occur during cancer or viral infection

Known as ASG-15ME, the ADC aims at the tumor antigen SLITRK6, which is known to be expressed on bladder and lung cancer. Seattle Genetics chief operating officer Eric

Janssen Immunology Therapeutic scientists and The Icahn School of Medicine researchers will jointly work to investigate disease triggers, identify new opportunities for therapeutic interventions and create diagnostics to

Approved for manufacturing and distribution, Lyxumia is a first once-daily prandial GLP-1 receptor agonist (RA) offering a new treatment option for the people living in the region with

Developed to treat adult patients with major depressive episodes associated with bipolar I disorder, Latuda has been approved for use as monotherapy and as adjunctive therapy with either

The completion of the transaction involved AstraZeneca to acquire 100% of Pearl’s shares and provides access to PT003, a probable new treatment for chronic obstructive pulmonary disease (COPD),